DRG Epidemiology’s coverage of urothelial cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of urothelial cancer for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of ten years for the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) and the other countries covered in this report. In addition to forecasting the incident patient population, we estimate the number of drug-treatment opportunities in the mature markets.
DRG Epidemiology’s urothelial cancer forecast will answer the following questions:
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following urothelial cancer patient populations:
… and many more (details available upon request).
Note: Coverage may vary by country and region.